兴齐眼药近视防控新药获准临床试验 行业竞争从“单品突围”转向“多元竞争”

Core Viewpoint - The competition among domestic pharmaceutical companies in the field of myopia prevention drugs is intensifying, with Xingqi Eye Medicine leading the market by obtaining multiple approvals for atropine eye drops and advancing new drug trials [2][3][4]. Group 1: Product Approvals and Market Position - Xingqi Eye Medicine was the first in China to receive approval for 0.01% atropine eye drops in March 2024, establishing a competitive edge in the myopia prevention market [2][4]. - The company has also received approvals for 0.02% and 0.04% concentrations of atropine eye drops, enhancing its market position through a gradient concentration strategy [2][4]. - The newly approved SQ-24071 eye drops for clinical trials represent a significant milestone in the drug development process, indicating the transition from laboratory research to human testing [2][3]. Group 2: Financial Performance - Since the launch of its atropine eye drops, Xingqi Eye Medicine has experienced substantial revenue growth, with a 32.42% increase in revenue and a 40.84% increase in net profit for 2024 compared to 2023 [4]. - In the first three quarters of 2025, the company reported a 32.27% year-on-year increase in revenue and a remarkable 105.98% increase in net profit [5]. Group 3: Industry Trends and Future Outlook - The rising incidence of myopia in China, driven by excessive use of electronic devices and poor eye care habits, has created a significant public health issue, prompting increased competition among pharmaceutical companies [3]. - The approval of SQ-24071 eye drops signifies a shift in the myopia prevention market from single-product competition to a comprehensive strategy involving product matrices and service ecosystems [5].